HT-29 - HTB-38 | ATCC (2024)

HTB-38

HT-29 is a cell line with epithelial morphology that was isolated in 1964 from a primary tumor obtained from a 44-year-old, White, female patient with colorectal adenocarcinoma. This cell line is a suitable transfection host and has applications in cancer and toxicology research.

Product category

Human cells

Organism

hom*o sapiens, human

Morphology
epithelial
Tissue
Colon
Disease

Adenocarcinoma; Colorectal

Applications

3D cell culture

Cancer research

High-throughput screening

Toxicology

Product format
Frozen
Storage conditions

Vapor phase of liquid nitrogen

See Additional Product Information

Buy Now

Price: €595.00EA

Documentation

Product sheet
Characterization data

Certificate of Analysis Download

To download a certificate of analysis for HT-29 (HTB-38), enter the lot number exactly as it appears on your product label or packing slip.

Certificate of Analysis Request

The certificate of analysis for that lot of HT-29 (HTB-38) is not currently available online. Complete this form to request this certificate of analysis.

We have received your request for this certificate of analysis. We will contact you as soon as possible.

You can find your account number on your sales order confirmation or order invoice.

Certificate of Origin Download

To download a certificate of origin for HT-29 (HTB-38), enter the lot number exactly as it appears on your product label or packing slip.

Certificate of Origin Request

The certificate of origin for that lot of HT-29 (HTB-38) is not currently available online. Complete this form to request this certificate of origin.

We have received your request for this certificate of origin. We will contact you as soon as possible.

You can find your account number on your sales order confirmation or order invoice.

This product sheet is not available online. We only provide this product sheet to customers who have purchased this biosafety level 3 product. If you purchased this product, please contact the LGC Technical Support team for this product sheet.

Safety Data Sheet Download

Open the Safety Data Sheet for this product to download.

HT-29 - HTB-38 | ATCC (1)

If a requested product is not a hazardous chemical, or does not contain any hazardous chemicals, a SDS is not required and therefore will not be provided.

Please check the Product Sheet and Safety Data Sheet Landing pagefor more information.

ATCC determines the biosafety level of a material based on our risk assessment as guided by the current edition of Biosafety in Microbiological and Biomedical Laboratories (BMBL), U.S. Department of Health and Human Services. It is your responsibility to understand the hazards associated with the material per your organization’s policies and procedures as well as any other applicable regulations as enforced by your local or national agencies.

ATCC highly recommends that appropriate personal protective equipment is always used when handling vials. For cultures that require storage in liquid nitrogen, it is important to note that some vials may leak when submersed in liquid nitrogen and will slowly fill with liquid nitrogen. Upon thawing, the conversion of the liquid nitrogen back to its gas phase may result in the vial exploding or blowing off its cap with dangerous force creating flying debris. Unless necessary, ATCC recommends that these cultures be stored in the vapor phase of liquid nitrogen rather than submersed in liquid nitrogen.

Jump to

Required Products

These products are vital for the proper use of this item and have been confirmed as effective in supporting functionality. If you use alternative products, the quality and effectiveness of the item may be affected.

McCoy's 5A Medium

30-2007

Fetal Bovine Serum (FBS)

30-2020

Related Products

Colon Cancer Panel 2, BRAF

TCP-1007

Detailed product information

Expand all Collapse all

General

Specific applications

This cell line is a suitable transfection host.

Characteristics

Growth properties
Adherent
Derivation

The HT-29 line was isolated from a primary tumor in 1964 by J. Fogh using the explant culture method.

Age
44 years
Ethnicity
White
Gender
Female
Karyotype
modal number = 71; range = 68 to 72.
The stemline chromosome number is hypertriploid with the 2S component occurring at 2.4%. Seventeen marker chromosomes are found in most metaphases, generally in single copy per chromosome. The marker designations are: M1p-(=t(3p-;?) with a deleted short arm), t(7q;?), t(10q;?), i(13q), 19q+a; M6, ?t(8q;9q-), ?Xp, M9, 6q+, t(13;?)a, t(13;?)b, 19q+b, M14, M15, 15p+, and Xq-. Chromosome 13 is nullisomic and chromosomes 8 and 14 are generally monosomic. No Y chromosome was detected by QM band analysis.
Tumorigenic
Yes;

Yes, in nude mice; forms well differentiated adenocarcinoma consistent with colonic primary (grade I); tumors also form in steroid treated hamsters

Oncogene
myc+; ras+; myb+; fos+; sis+; p53+; abl-; ros-; src-
Antigen expression

Blood Type A; Rh+; HLA A1, A3, B12, B17, Cw5

Genes expressed
secretory component of IgA; carcinoembryonic antigen (CEA); transforming growth factor beta binding protein; mucin; myc+; ras+; myb+; fos+; sis+; p53+; abl-; ros-; src-; blood type A; Rh+; (HLA: A1; A3; B12; B17; Cw5); cells CD4 negative; cell surface expression of galactose ceramide (a possible alternative receptor for HIV)
Expression markers
human adrenergic alpha2A; urokinase receptor (u-PAR); vitamin D (moderate expression); urokinase receptor (u-PAR); human adrenergic alpha2A
Isoenzymes

AK-1, 1

ES-D, 1

G6PD, B

GLO-I, 1-2

Me-2, 1

PGM1, 1-2

PGM3, 1-2

Comments

Ultrastructural features reported for HT-29 cells include microvilli, microfilaments, large vacuolated mitochondria with dark granules, smooth and rough endoplasmic reticulum with free ribosomes, lipid droplets, few primary and many secondary lysosomes.

The cells express urokinase receptors, but do not have detectable plasminogen activator activity [PubMed ID: 8381394]. HT-29 cells are negative for CD4, but there is cell surface expression of galactose ceramide (a possible alternative receptor for HIV).

The line is positive for expression of c-myc, K-ras, H-ras, N-ras, Myb, sis and fos oncogenes. The p53 antigen is overproduced, and there is a G -> A mutation in codon 273 of the p53 gene resulting in an Arg -> His substitution. N-myc oncogene expression was not detected.

There is a G -> A mutation in codon 273 of the p53 gene resulting in an Arg -> His substitution.

Technical information

ATCC Technical Services does not have technical information on patent deposits that are not produced or characterized by ATCC. Additional information can be found in the corresponding patent available from the patent holder or with the U.S. and/or international patent office.

Handling information

Unpacking and storage instructions
  1. Check all containers for leakage or breakage.
  2. Remove the frozen cells from the dry ice packaging and immediately place the cells at a temperature below ­-130°C, preferably in liquid nitrogen vapor, until ready for use.
Complete medium
The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature

37°C

Atmosphere

95% Air, 5% CO2

Handling procedure

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

  1. Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 minutes).
  2. Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
  3. Transfer the vial contents to a centrifuge tube containing 9.0 mL complete culture medium. and spin at approximately 125 x g for 5 to 7 minutes.
  4. Resuspend cell pellet with the recommended complete medium (see the specific batch information for the culture recommended dilution ratio). and dispense into a 25 cm2 culture flask. It is important to avoid excessive alkalinity of the medium during recovery of the cells. It is suggested that, prior to the addition of the vial contents, the culture vessel containing the complete growth medium be placed into the incubator for at least 15 minutes to allow the medium to reach its normal pH (7.0 to 7.6). pH (7.0 to 7.6).
  5. Incubate the culture at 37°C in a suitable incubator. A 5% CO2 in air atmosphere is recommended if using the medium described on this product sheet.
Subculturing procedure
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).Corning® T-75 flasks (catalog #430641) are recommended for subculturing this product.
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended

Medium Renewal: 2 to 3 times per week

Reagents for cryopreservation
Complete growth medium, 95%; DMSO, 5%

Quality control specifications

Mycoplasma contamination
Not detected
STR profiling
Amelogenin: X CSF1PO: 11,12 D13S317: 11,12 D16S539: 11,12 D5S818: 11,12 D7S820: 10 TH01: 6,9 TPOX: 8,9 vWA: 17,19 D3S1358: 15,17 D21S11: 29,30 D18S51: 13 Penta_E: 14,16 Penta_D: 11,13 D8S1179: 10,16 FGA: 20,22 D19S433: 14 D2S1338: 19,23

History

Deposited as
hom*o sapiens
Depositors
J Fogh
Year of origin
1964
Special collection

Human Tumor Cell Bank

Legal disclaimers

Intended use
This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use.
Warranty

The product is provided 'AS IS' and the viability of ATCC® products is warranted for 30 days from the date of shipment, provided that the customer has stored and handled the product according to the information included on the product information sheet, website, and Certificate of Analysis. For living cultures, ATCC lists the media formulation and reagents that have been found to be effective for the product. While other unspecified media and reagents may also produce satisfactory results, a change in the ATCC and/or depositor-recommended protocols may affect the recovery, growth, and/or function of the product. If an alternative medium formulation or reagent is used, the ATCC warranty for viability is no longer valid. Except as expressly set forth herein, no other warranties of any kind are provided, express or implied, including, but not limited to, any implied warranties of merchantability, fitness for a particular purpose, manufacture according to cGMP standards, typicality, safety, accuracy, and/or noninfringement.

Disclaimers

This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. Any proposed commercial use is prohibited without a license from ATCC.

While ATCC uses reasonable efforts to include accurate and up-to-date information on this product sheet, ATCC makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. ATCC does not warrant that such information has been confirmed to be accurate or complete and the customer bears the sole responsibility of confirming the accuracy and completeness of any such information.

This product is sent on the condition that the customer is responsible for and assumes all risk and responsibility in connection with the receipt, handling, storage, disposal, and use of the ATCC product including without limitation taking all appropriate safety and handling precautions to minimize health or environmental risk. As a condition of receiving the material, the customer agrees that any activity undertaken with the ATCC product and any progeny or modifications will be conducted in compliance with all applicable laws, regulations, and guidelines. This product is provided 'AS IS' with no representations or warranties whatsoever except as expressly set forth herein and in no event shall ATCC, its parents, subsidiaries, directors, officers, agents, employees, assigns, successors, and affiliates be liable for indirect, special, incidental, or consequential damages of any kind in connection with or arising out of the customer's use of the product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, ATCC is not liable for damages arising from the misidentification or misrepresentation of such materials.

Please see the material transfer agreement (MTA) for further details regarding the use of this product. The MTA is available at www.atcc.org.

Disclosures

This material is cited in a US and/or international patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Depositor of the party to which the material was furnished.

Permits & Restrictions

The Memorial Sloan-Kettering Cancer Center releases this material subject to the following restrictions in addition to those outlined in the ATCC Material Transfer Agreement:

  1. Transfers - The cells or their products must not be transferred to third parties.
  2. Commercial Use - all for-profit and non-profit Recipients must obtain a commercial use license prior to Commercial Use.

Any proposed Commercial Use of these cells must first be negotiated with:

Memorial Sloan-Kettering Cancer Center
Office of Technology Development
1275 York Avenue
New York, NY 10065
Email: [emailprotected]

MORE INFORMATION ABOUT PERMITS AND RESTRICTIONS

Images

HT-29 - HTB-38 | ATCC (3)

HT-29 - HTB-38 | ATCC (4)

Frequently Asked Questions

Expand ALL Collapse ALL

<%= content.replace(regex, "") %>

View the Additional FAQs View all our FAQs

References

Didier ES, et al. Characterization of Encephalitozoon (Septata) intestinailis isolates cultured from nasal mucosa and bronchoalveolar lavage fluids of two AIDS patients. J. Eukaryot. Microbiol. 43: 34-43, 1996. PubMed: 8563708

Fogh J. Human tumor cells in vitro. New York: Plenum Press; 1975.

Chen TR, et al. WiDr is a derivative of another colon adenocarcinoma cell line, HT-29. Cancer Genet. Cytogenet. 27: 125-134, 1987. PubMed: 3472642

Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871

Goodfellow M, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 77210034

Adachi A, et al. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J. Virol. 61: 209-213, 1987. PubMed: 3640832

Fantini J, et al. Human colon epithelial cells productively infected with human immunodeficiency virus show impaired differentiation and altered secretion. J. Virol. 66: 580-585, 1992. PubMed: 1727501

Butzow R, et al. A 60-kD protein mediates the binding of transforming growth factor-beta to cell surface and extracellular matrix proteoglycans. J. Cell Biol. 122: 721-727, 1993. PubMed: 8335695

Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874

Hanski C, et al. Tumorigenicity, mucin production and AM-3 epitope expression in clones selected from the HT-29 colon carcinoma cell line. Int. J. Cancer 50: 924-929, 1992. PubMed: 1372882

Reiter LS, et al. The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells. Int. J. Cancer 53: 444-450, 1993. PubMed: 8381394

Barnett SW, et al. Characterization of human immunodeficiency virus type 1 strains recovered from the bowel of infected individuals. Virology 182: 802-809, 1991. PubMed: 2024498

Shabahang M, et al. 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res. 53: 3712-3718, 1993. PubMed: 8393379

Lesuffleur T, et al. Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT- 29 cell subpopulations. J. Cell Sci. 106: 771-778, 1993. PubMed: 8308060

Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212

Fantini J, et al. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc. Natl. Acad. Sci. USA 90: 2700-2704, 1993. PubMed: 8464878

Devedjian JC, et al. Regulation of the alpha 2A-adrenergic receptor in the HT29 cell line. Effects of insulin and growth factors. J. Biol. Chem. 266: 14359-14366, 1991. PubMed: 1677644

Santoro IM, Groden J. Alternative splicing of the APC gene and its association with terminal differentiation. Cancer Res. 57: 488-494, 1997. PubMed: 9012479

Bermudez LE, et al. Exposure to low oxygen tension and increased osmolarity enhance the ability of Mycobacterium avium to enter intestinal epithelial (HT-29) cells. Infect. Immun. 65: 3768-3773, 1997. PubMed: 9284150

Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066

Qian XC, Brent TP. Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res. 57: 3672-3677, 1997. PubMed: 9288770

Morin PJ, et al. Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. USA 93: 7950-7954, 1996. PubMed: 8755583

White LJ, et al. Attachment and entry of recombinant norwalk virus capsids to cultured human and animal cell lines. J. Virol. 70: 6589-6597, 1996. PubMed: 8794293

Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128

Wang R, et al. Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. Proc. Natl. Acad. Sci. USA 93: 8425-8430, 1996. PubMed: 8710887

Young SW, et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc. Natl. Acad. Sci. USA 93: 6610-6615, 1996. PubMed: 8692865

Groh V, et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93: 12445-12450, 1996. PubMed: 8901601

Takahashi K, et al. Keratan sulfate modification of CD44 modulates adhesion to hyaluronate. J. Biol. Chem. 271: 9490-9496, 1996. PubMed: 8621620

References

Curated Citations

Didier ES, et al. Characterization of Encephalitozoon (Septata) intestinailis isolates cultured from nasal mucosa and bronchoalveolar lavage fluids of two AIDS patients. J. Eukaryot. Microbiol. 43: 34-43, 1996. PubMed: 8563708

Fogh J. Human tumor cells in vitro. New York: Plenum Press; 1975.

Chen TR, et al. WiDr is a derivative of another colon adenocarcinoma cell line, HT-29. Cancer Genet. Cytogenet. 27: 125-134, 1987. PubMed: 3472642

Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871

Goodfellow M, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 77210034

View All Curated Citations for this Product

  • Does all Disease Begin in the Gut? Monitoring the Barrier Function of an In Vitro Gut Mimic
  • Integrating ATCC Authenticated Cell Lines into your CRISPR Gene Editing Workflows
  • 3-D Dermal Models
  • Coming Soon Products
  • Novel 3-D In Vitro Models for Studying Pancreatic Cancer Drug Response and Resistance
  • Breast Cancer Resource Book
  • Cancer Immunology Research Tools
  • Toxicology Portfolio
  • AACR Annual Meeting
View All Resources
HT-29 - HTB-38 | ATCC (6) HT-29 - HTB-38 | ATCC (7)

Need assistance with this product? Contact the LGC Technical Support team.

HT-29 - HTB-38 | ATCC (8)

Email

Send us a message

HT-29 - HTB-38 | ATCC (9)

Telephone

+44 (0) 20 8943 8489

HT-29 - HTB-38 | ATCC (2024)
Top Articles
Latest Posts
Article information

Author: Greg Kuvalis

Last Updated:

Views: 6068

Rating: 4.4 / 5 (55 voted)

Reviews: 94% of readers found this page helpful

Author information

Name: Greg Kuvalis

Birthday: 1996-12-20

Address: 53157 Trantow Inlet, Townemouth, FL 92564-0267

Phone: +68218650356656

Job: IT Representative

Hobby: Knitting, Amateur radio, Skiing, Running, Mountain biking, Slacklining, Electronics

Introduction: My name is Greg Kuvalis, I am a witty, spotless, beautiful, charming, delightful, thankful, beautiful person who loves writing and wants to share my knowledge and understanding with you.